Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial

Lancet

Volumn 359, Issue 9324, 2002, Pages 2131-2139

  Baum, M ^b   Buzdar, A U ^b   Cuzick, J ^b   Forbes, J ^b   Houghton, J ^a   Klijn, J G M ^b   Sahmoud, T ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 0037157603     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09088-8     Document Type: Article

References (28)

1. Endocrine treatment of breast cancer in women
2. Recent advances in endocrine therapy of breast cancer
3. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer
4. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
5. Tamoxifen for early breast cancer: An overview of the randomised trials
6. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
7. Tamoxifen and endometrial cancer
8. Gynaecological monitoring during tamoxifen therapy
9. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
10. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
11. Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: Occurrence of thromboembolic complications
12. Tamoxifen and risk of idiopathic venous thromboembolism
13. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer
14. For the Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
15. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
16. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
17. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis
18. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women (part I)
19. Tamoxifen therapy for breast cancer and endometrial cancer risk
20. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-group of the 'Arimidex' and Tamoxifen Alone or in Combination (ATAC) trial
21. Tamoxifen and contralateral breast cancer
22. Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
23. Aromatase inhibitors and arthralgia
24. Rheumatoid symptoms following breast cancer treatment: A controlled comparison
25. Postchemotherapy Rheum
26. Menopause, oestrogens and arthritis
27. How are bisphosphonates used today in breast cancer clinical practice?
28. The effect of anastrozole ('Arimidex') on serum lipids: A randomized comparison of anastrozole (AN) vs. tamoxifen (TAM) in postmenopausal women with advanced breast cancer